Tango Therapeutics, Inc.
TNGX
Ранг среди акций
#4543
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Цена акции
$27.18
Последняя синхронизация: 2026-07-31
Рыночная капитализация
$3.38B
Изменение (1 день)
-1.41%
Изменение (1 год)
202.34%
Страна
US
Торговля Tango Therapeutics, Inc. (TNGX)
Категория
Healthcare
История дроблений акций Tango Therapeutics, Inc. (TNGX)
Акции Tango Therapeutics, Inc. (символ: TNGX) прошли через 0 дроблений.
Последнее дробление произошло Oct 21, 2026.
Одна акция TNGX, купленная до Oct 21, 2026, сейчас соответствует 0 акциям TNGX.
Последнее дробление произошло Oct 21, 2026.
Одна акция TNGX, купленная до Oct 21, 2026, сейчас соответствует 0 акциям TNGX.
Список дроблений акций
| Год | Дробление | Коэффициент | Суммарный коэффициент |
|---|---|---|---|
| Недостаточно данных для указанных дат. | |||
Дробления акций аналогичных компаний или конкурентов
| Компания | Количество дроблений акций | Суммарный коэффициент | Страна |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
